What is Actinium Pharmaceuticals Inc (ATNM) stock price today?

Actinium Pharmaceuticals Inc (ATNM) currently trades at $1.12 per share. The stock has a market capitalization of $40.16M and a P/E ratio of —x.

Is ATNM stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Actinium Pharmaceuticals Inc has a Smart Value Score of 14/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Actinium Pharmaceuticals Inc's revenue and earnings?

Actinium Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $90000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-1.09.

ATNM

Actinium Pharmaceuticals Inc

NYSE MKT: ATNM · HEALTHCARE · BIOTECHNOLOGY

$1.12

-4.70% today

Updated 2026-04-30

Market cap

$40.16M

P/E ratio

—

P/S ratio

446.22x

EPS (TTM)

$-1.09

Dividend yield

—

52W range

$1 – $2

Volume

0.2M

Market cap

$40.16M

P/E ratio

—

P/S ratio

446.22x

EPS (TTM)

$-1.09

Dividend yield

—

52W range

$1 – $2

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$5.00

+348.43%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-5.39M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$1.03M	$81000.00	$0.00	$90000.00	$90000.00
Net income	$-33.02M	$-48.82M	$-38.24M	$-33.89M	$-5.94M
EPS	—	—	—	—	$-1.09
Free cash flow	$8.28M	$-47.49M	$-33.08M	$-24.68M	$-5.39M
Profit margin	-3,205.53%	-60,269.14%	—	-37,652.22%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ATNM	$40.16M	14	2.7	2.5	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Actinium Pharmaceuticals Inc trades at $1.12. Our Smart Value Score of 14/100 indicates the stock is weak. TTM revenue stands at $90000.00.

Frequently asked questions

What is Actinium Pharmaceuticals Inc's stock price?

Actinium Pharmaceuticals Inc (ATNM) trades at $1.12.

Is Actinium Pharmaceuticals Inc overvalued?

Smart Value Score 14/100 (Grade F, Strong Sell).

What is the price target of Actinium Pharmaceuticals Inc (ATNM)?

The analyst target price is $5.00, representing +348.4% upside from the current price of $1.12.

What is Actinium Pharmaceuticals Inc's revenue?

TTM revenue is $90000.00.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNYSE MKT

CurrencyUSD

Quick metrics

P/S ratio446.22x

ROE-167.00%

Beta-0.21

50D MA$1.15

200D MA$1.41

Shares out0.03B

Float0.03B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ATNM vs LLY →ATNM vs JNJ →ATNM vs ABBV →Stock screener →